Prostemics Co. Ltd (203690) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.036x

Based on the latest financial reports, Prostemics Co. Ltd (203690) has a cash flow conversion efficiency ratio of -0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-900.50 Million ≈ $-610.25K USD) by net assets (₩24.87 Billion ≈ $16.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View 203690 stock price and chart for real-time trading data and today's change.

Prostemics Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Prostemics Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market value of Prostemics Co. Ltd for the company's overall valuation and market capitalisation.

Prostemics Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Prostemics Co. Ltd ranked by their cash flow conversion efficiency. Also see total assets of Prostemics Co. Ltd for a full breakdown of the balance sheet.

Company	Cash Flow Conversion Efficiency
BT Wealth Industries Public Company Limited BK:BTW	-0.044x
Savoreat Ltd TA:SVRT	-0.762x
Engineer Gold Mines Ltd V:EAU	0.009x
KINGS ENTERTAINMENT GROUP F:L12	N/A
Steakholder Foods Ltd NASDAQ:STKH	-0.320x
Nexera Energy Inc V:NGY	-0.007x
Lucas GC Limited Ordinary Shares NASDAQ:LGCL	0.064x
NewGenIvf Group Limited Class A Ordinary Shares NASDAQ:NIVF	-0.245x

Annual Cash Flow Conversion Efficiency for Prostemics Co. Ltd (2015–2025)

The table below shows the annual cash flow conversion efficiency of Prostemics Co. Ltd from 2015 to 2025. Review Prostemics Co. Ltd (203690) flexibility index to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩25.96 Billion ≈ $17.59 Million	₩-10.11 Billion ≈ $-6.85 Million	-0.390x	-426.57%
2024-12-31	₩25.94 Billion ≈ $17.58 Million	₩-1.92 Billion ≈ $-1.30 Million	-0.074x	+67.06%
2023-12-31	₩30.43 Billion ≈ $20.62 Million	₩-6.84 Billion ≈ $-4.63 Million	-0.225x	+53.77%
2022-12-31	₩9.83 Billion ≈ $6.66 Million	₩-4.78 Billion ≈ $-3.24 Million	-0.486x	-325.35%
2021-12-31	₩13.93 Billion ≈ $9.44 Million	₩3.00 Billion ≈ $2.04 Million	0.216x	+199.11%
2020-12-31	₩21.47 Billion ≈ $14.55 Million	₩-4.67 Billion ≈ $-3.17 Million	-0.218x	-1349.04%
2019-12-31	₩28.35 Billion ≈ $19.21 Million	₩-425.74 Million ≈ $-288.52K	-0.015x	+79.48%
2018-12-31	₩31.89 Billion ≈ $21.61 Million	₩-2.33 Billion ≈ $-1.58 Million	-0.073x	+13.86%
2017-12-31	₩39.16 Billion ≈ $26.54 Million	₩-3.33 Billion ≈ $-2.25 Million	-0.085x	-164.99%
2016-12-31	₩44.86 Billion ≈ $30.40 Million	₩5.86 Billion ≈ $3.97 Million	0.131x	-17.60%
2015-12-31	₩39.38 Billion ≈ $26.69 Million	₩6.25 Billion ≈ $4.23 Million	0.159x	--

About Prostemics Co. Ltd

KQ:203690 Korea Biotechnology

Market Cap

$1.88 Million

₩2.78 Billion KRW

Market Cap Rank

#30129 Global

#2101 in Korea

Share Price

₩139.00

Change (1 day)

+0.00%

52-Week Range

₩139.00 - ₩139.00

All Time High

₩77250.00